Trial Profile
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMERALD
- Sponsors Eisai Co Ltd
- 15 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 29 Jun 2020 Planned End Date changed from 30 Apr 2024 to 30 Jun 2024.
- 05 Sep 2019 Planned End Date has been changed to 30 Apr 2024.